REFERENCES
1. Lilly L.S. Pathophysiology of the Cardiovascular System. Transl. from Engl. Moscow: BINOM, Laboratoriay znaniy, 2016: 182–218. ISBN 978-5-9963-0726-5. (in Russian)
2. Hermans M.P., et al. Residual microvascular risk in type 2 diabetes in 2014: is it time for a re-think? A perspective from the residual risk reduction initiative (R3i). J Diabetes Metab. 2014; 5: 8. DOI: https://doi.org/10.4172/2155-6156.1000413
3. Ference B.A., Ginsberg H.N., et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017; 38 (32): 2459–72. DOI: https://doi.org/10.1093/eurheartj/ehx144
4. Poznyak A., et al. The diabetes mellitus–atherosclerosis connection: the role of lipid and glucose metabolism and chronic inflammation. Int J Mol Sci. 2020; 21 (5): 1835. DOI: https://doi.org/10.3390/ijms21051835
5. van den Berg M.J., et al. Low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, triglycerides, and apolipoprotein B and cardiovascular risk in patients with manifest arterial disease. Am J Cardiol. 2016; 118 (6): 804–10. DOI: https://doi.org/10.1016/j.amjcard.2016.06.048
6. Sattar N. Comparison of the associations of apolipoprotein B and non-high-density lipoprotein cholesterol with other cardiovascular risk factors in patients with the metabolic syndrome in the Insulin Resistance Atherosclerosis Study. Circulation. 2004; 110: 2687–93. DOI: https://doi.org/10.1161/01.CIR.0000145660.60487.94
7. Bhatt D.L. REDUCE-IT: residual cardiovascular risk in statin-treated patients with elevated triglycerides: now we can REDUCE-IT! Eur Heart J. 2019; 40 (15): 1174–5. DOI: https://doi.org/10.1093/eurheartj/ehz179
8. Langlois M.R., et al. Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM for the European Atherosclerosis Society (EAS) and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM). Clin Chem Lab Med. 2020; 294: 46–61. DOI: https://doi.org/10.1515/cclm-2019-1253
9. Pencina K.M., et al. Trajectories of non-HDL cholesterol across midlife: implications for cardiovascular prevention. J Am Coll Cardiol. 2019; 74 (1): 70–9. DOI: https://doi.org/10.1016/j.jacc.2019.04.047
10. Carr S.S. Non-HDL-cholesterol and apolipoprotein B compared with LDL-cholesterol in atherosclerotic cardiovascular disease risk assessment. Pathology. 2019; 51 (2): 148–54. DOI: https://doi.org/10.1016/j.pathol.2018.11.006
11. Shapiro M.D., Fazio S. From lipids to inflammation. Circ Res. 2016. 118: 732–49. DOI: https://doi.org/10.1161/CIRCRESAHA.115.306471
12. Tsimikas S., et al. NHLBI working group recommendations to reduce lipoprotein(a)-mediated risk of cardiovascular disease and aortic stenosis. J Am Coll Cardiol. 2018; 71: 177–92. DOI: https://doi.org/10.1016/j.jacc.2017.11.014
13. Burgess S. Association of LPA variants with risk of coronary disease and the implications for lipoprotein (a)-lowering therapies: a Mendelian randomization analysis. JAMA Cardiol. 2018; 3 (7): 619–27. DOI: https://doi.org/10.1001/jamacardio.2018.1470
14. Nordestgaard B.G., et al. Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM. Atherosclerosis. 2020; 294: 46–61. DOI: https://doi.org/10.1016/j.atherosclerosis.2019.12.005
15. Kukharchuk V.V., Ezhov M.V., et al. Diagnostics and correction of lipid metabolism disorders for the prevention and treatment of atherosclerosis. Russian recommendations, VII revision. Ateroskleroz i dislipidemii [Atherosclerosis and Dyslipidemia]. 2020; 1 (38): 7–42. DOI: https://doi.org/10.34687/2219-8202.JAD.2020.01.0002 (in Russian)
16. Stam-Slob M.C. Effect of type 2 diabetes on recurrent major cardiovascular events for patients with symptomatic vascular disease at different locations. Diabetes Care. 2015; 38: 1528–35. DOI: https://doi.org/10.2337/dc14-2900
17. Wan Z., Fan Y., et al. NLRP3 inflammasome promotes diabetes-induced endothelial inflammation and atherosclerosis. Diabetes Metab Syndr Obes. 2019; 12: 1931–42. DOI: https://doi.org/10.2147/DMSO.S222053
18. Feng H., et al. High glucose and lipopolysaccharide prime NLRP3 inflammasome via ROS/TXNIP pathway in mesangial cells. J Diabetes Res. 2016; 2016: 6973175. DOI: https://doi.org/10.1155/2016/6973175
19. Bornfeldt K.E. Does elevated glucose promote atherosclerosis? Pros and Cons. Circ Res. 2016; 119 (2): 190–3. DOI: https://doi.org/10.1161/CIRCRESAHA.116.308873
20. Wolf D., Ley K. Immunity and inflammation in atherosclerosis. Circ Res. 2019; 124: 315–27. DOI: https://doi.org/10.1161/CIRCRESAHA.118.313591
21. Menon V., Kumar A. Impact of baseline glycemic control on residual cardiovascular risk in patients with diabetes mellitus and high‐risk vascular disease treated with statin therapy. J Am Heart Assoc. 2020; 9 (1): e014328. DOI: https://doi.org/10.1161/JAHA.119.014328
22. Wolf D., et al. Immunity and Inflammation in atherosclerosis. Circ Res. 2019; 124 (2): 315–27. DOI: https://doi.org/10.1161/CIRCRESAHA.118.313591